Citadel Advisors’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Citadel Advisors’s Portfolio SGTX Stock Details SGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,575	Closed	-$26.7K	–	15961
2022 Q4	$11.7K	Buy	+2,575	New	+$14.7K	﹤0.01%	13555
2022 Q3	–	Sell	-3,603	Closed	-$32.9K	–	14024
2022 Q2	$39K	Buy	+3,603	New	+$48.4K	﹤0.01%	12085
2022 Q1	–	Sell	-838	Closed	-$30K	–	15013
2021 Q4	$30K	Buy	+838	New	+$47.7K	﹤0.01%	13481
2021 Q3	–	Sell	-1,111	Closed	-$85.5K	–	14980
2021 Q2	$155K	Buy	1,111 +407	+58%	+$71.5K	﹤0.01%	12473
2021 Q1	$204K	Buy	+704	New	+$280K	﹤0.01%	11658

Other funds holding SGTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's SGTX Position: Q1 2023 in Review

Citadel Advisors sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q1 2023, closing a stake of 2,575 shares — an estimated $26.7K sold.

Citadel Advisors first reported a position in SGTX in Q1 2021 and held it in 5 quarters. The position peaked at $204K in Q1 2021. 32 funds tracked by Wall St. Rank hold SGTX as of Q1 2023.

Citadel Advisors reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Citadel Advisors sold 2,575 Sigilon Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $26.7K.
Citadel Advisors first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
Citadel Advisors's Sigilon Therapeutics, Inc. Common Stock position peaked at $204K in Q1 2021.
32 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.